ARCHIVES

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

This article is from The Cancer Letter archive.

Vol. 31 No. 01 | January 7, 2005

Download PDF Visit The Full Archive

Related Articles

Campath Improves PFS In B-Cell CLL In Phase III Trial

January 26, 2007

Xeloda As Effective As 5-FU/LV, Five-Year Survival Data Show

September 28, 2007

Bennett Of NYU Heads NCI Director Search Committee

March 11, 1977

Budget Projections for 1978 Offer Clues On Research NCI Hopes To Fund

June 18, 1976

Senate committee approves $1.1 billion increase for NIH.

October 1, 2004

In Brief: Megastrol Acetate Still Under FDA Review; Mays Hired For NCI’s Technology Office

July 20, 1990